If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"Individuals with cancer events","arm_group_description":"Cancer events include: malignancy, acquired immunodeficiency syndrome (AIDS)-defining malignancy (ADM), Kaposi’s sarcoma, Non-Hodgkin’s lymphoma, cervical cancer, non-AIDS-defining malignancy (NADM), lung cancer, anal cancer, Hodgkin’s lymphoma, head and neck cancer.","arm_type":""},{"arm_group_label":"Hepatically-impaired individuals with safety issues","arm_group_description":"Safety issues include: clinical liver events (end stage liver disease [ESLD] or hepatocellular carcinoma [HCC]), any cardiovascular (CV) event, diabetes, cancer, end-stage renal disease (ESRD), mortality events.","arm_type":""},{"arm_group_label":"Individuals with ischemic cardiac events","arm_group_description":"Ischemic cardiac events include: myocardial infarction (MI) and/or sudden cardiovascular death.","arm_type":""},{"arm_group_label":"Individuals with hepatotoxicity events","arm_group_description":"Hepatotoxicity events include: clinical liver endpoint: ESLD/HCC, laboratory-defined chronic liver enzyme elevation (CLEE).","arm_type":""}],"assignment":"","brief_summary":"To meet the regulatory commitments for marketed products (trademarks owned by ViiV Healthcare and the GlaxoSmithKline group of companies) -Ziagen® (abacavir), Kivexa® (abacavir/lamivudine), Trizivir® (abacavir/lamivudine/zidovudine), Combivir® (zidovudine/lamivudine), Telzir® (fosamprenavir) and Celsentri® (maraviroc), a study will be conducted to analyze long term drug specific safety outcomes. It will be a retrospective analysis of prospectively collected data from the D:A:D (Data collection on Adverse events of anti- HIV Drugs) study which contains data from nearly 50,000 HIV-positive patients.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Post-marketing safety analyses for multiple marketed products in collaboration with the D:A:D study","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 21:20:09","criteria":"Inclusion Criteria: - Participants who have evidence of co-infection with HBV/ HCV and/or CLEEs at the time of initiating one of the three treatments/combinations - Participants without a prior cancer at D:A:D study enrolment who are enrolled from cohorts that provide data on cancer incidence - Participants without liver impairment (hepatotoxicity includes ESLD, HCC, and CLEE) or without a prior MI at D:A:D study entry Exclusion Criteria: - Participants from cohorts that do not provide information on ALT levels - Participants who have died or are lost-to-follow-up before the cohort-specific baseline date for cancer analyses.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Planned","display_status_internal":"RECSTATUS_O_PLANNED","endpoint":"","enrollment":"1","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"none","id":"04be2492-b1f5-5a6a-a190-806e65438247","internal":{"content":null,"contentDigest":"e0380b4c2e5fd5e11b6852661bda9955","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Participants who have evidence of co-infection with HBV/ HCV and/or CLEEs at the time of initiating one of the three treatments/combinations - Participants without a prior cancer at D:A:D study enrolment who are enrolled from cohorts that provide data on cancer incidence - Participants without liver impairment (hepatotoxicity includes ESLD, HCC, and CLEE) or without a prior MI at D:A:D study entry Exclusion Criteria: - Participants from cohorts that do not provide information on ALT levels - Participants who have died or are lost-to-follow-up before the cohort-specific baseline date for cancer analyses.","interventions":[{"arm_group_label":"Hepatically-impaired individuals with safety issues","intervention_description":"Participants whose current regimen includes fosamprenavir, regardless of other drugs in the regimen.","intervention_name":"Fosamprenavir regimen","intervention_type":"drug"},{"arm_group_label":"Individuals with ischemic cardiac events","intervention_description":"Participants whose current regimen includes fosamprenavir, regardless of other drugs in the regimen.","intervention_name":"Fosamprenavir regimen","intervention_type":"drug"},{"arm_group_label":"Individuals with hepatotoxicity events","intervention_description":"Participants whose current regimen includes fosamprenavir, regardless of other drugs in the regimen.","intervention_name":"Fosamprenavir regimen","intervention_type":"drug"},{"arm_group_label":"Individuals with cancer events","intervention_description":"Participants whose current regimen includes combination of 3TC+AZT, regardless of other drugs in the regimen.","intervention_name":"Zidovudine/lamivudine combination regimen","intervention_type":"drug"},{"arm_group_label":"Individuals with cancer events","intervention_description":"Participants whose current regimen includes; only ABC or ABC+lamivudine (3TC) or ABC+3TC+zidovudine (AZT), regardless of other drugs in the regimen.","intervention_name":"Abacavir (ABC) containing product regimen","intervention_type":"drug"},{"arm_group_label":"Hepatically-impaired individuals with safety issues","intervention_description":"Participants whose current regimen includes; only ABC or ABC+lamivudine (3TC) or ABC+3TC+zidovudine (AZT), regardless of other drugs in the regimen.","intervention_name":"Abacavir (ABC) containing product regimen","intervention_type":"drug"},{"arm_group_label":"Individuals with ischemic cardiac events","intervention_description":"Participants whose current regimen includes maraviroc, regardless of other drugs in the regimen.","intervention_name":"Maraviroc regimen","intervention_type":"drug"},{"arm_group_label":"Individuals with hepatotoxicity events","intervention_description":"Participants whose current regimen includes maraviroc, regardless of other drugs in the regimen.","intervention_name":"Maraviroc regimen","intervention_type":"drug"}],"interventional_subtype":"","is_fda_regulated":true,"is_high_value":false,"is_ind_study":false,"keywords":["ischemic cardiac events","D:A:D study","hepatotoxicity","carcinogenicity"],"last_follow_up_date":"07/28/2017 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"10/01/2018 22:44:18","number_of_arms":"0","observational_design":{"biospecimen_description":"Not applicable","biospecimen_retention":"None retained","number_of_groups":"0","observational_study_design":"Cohort","patient_registry":"false","target_duration_quantity":"","target_duration_units":"","timing":"Retrospective"},"official_title":"Post-marketing safety analyses for multiple marketed products in collaboration with the D:A:D study","org_study_id":"206247","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Not yet recruiting - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"phase 4","primary_compl_date":"07/28/2017 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Safety issues among hepatically-impaired individuals exposed to abacavir containing products and fosamprenavir","outcome_time_frame":"18 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Cancer events in patients exposed to abacavir containing products and zidovudine/lamivudine","outcome_time_frame":"18 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Hepatotoxicity events in patients exposed to maraviroc and fosamprenavir","outcome_time_frame":"18 years","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Ischemic cardiac events in patients exposed to maraviroc and fosamprenavir","outcome_time_frame":"18 years","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Hepatic dysfunction as indicated by liver chemistry tests","outcome_time_frame":"18 years","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["N/A","GSK"]},"start_date":"04/27/2017 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":false}},"pageContext":{"studyId":"206247"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}